Elsalys Biotech SA:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Elsalys Biotech SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C11275)・商品コード:DATA904C11275
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:28
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Elsalys Biotech SA (Elsalys Biotech) is a pharmaceutical company that develops new generation antibodies to modulate the immune system of patients with cancer or rare haematological diseases. The company’s pipeline programs include anti-CD160, for macular degeneration or certain retinopathies; anti-CD160, for solid tumors and blood cancer; anti-Tyro3, for solid tumors; and anti-S100b, for idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. It also develops Leukotac, an immunotherapy antibody developed for the treatment of orphan disease with very poor prognosis: steroid-resistant acute graft versus host disease. Elsalys Biotech’s specialization spans from target sourcing to the pre-industrial production of drug candidates. The company works in collaboration with academic and other industry partners to conduct programs, clinical evaluation of antibody candidates and to develop immune-based therapies. Elsalys Biotech is headquartered in Lyon, France.

Elsalys Biotech SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Elsalys Biotech SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 10
ElsaLys Biotech Acquires Rights of Anti-CD160 Antibody from MabLife 11
Venture Financing 12
ElsaLys Biotech Raises Additional USD3 Million in Financing Round 12
ElsaLys Biotech Raises US$2.7 Million In First Round Of Financing 13
Licensing Agreements 15
Laboratoires Thea Enters into Licensing Option Agreement with Elsalys Biotech 15
Elsalys Biotech Enters into Licensing Agreement with Transgene 16
ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 17
Equity Offering 18
Elsalys Biotech Files Registration Statement to Raise Funds in IPO 18
Acquisition 19
Transgene Acquires 37% Stake in ElsaLys Biotech 19
Elsalys Biotech SA – Key Competitors 20
Elsalys Biotech SA – Key Employees 21
Elsalys Biotech SA – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Corporate Communications 23
Jan 30, 2017: Elsalys Biotech expands its team to strengthen its strategy and the development of its programs 23
Product News 25
04/05/2018: Elsalys Biotech: LEUKOTAC takes next step in paediatric acute steroid-resistant GvHD 25
03/15/2018: EUKOTAC at the 44th Congress of the European Society for Blood and Marrow Transplantation (EBMT) 26
Clinical Trials 27
Jul 18, 2017: ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Key Facts 2
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Elsalys Biotech SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Elsalys Biotech SA, Deals By Therapy Area, 2012 to YTD 2018 8
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 10
ElsaLys Biotech Acquires Rights of Anti-CD160 Antibody from MabLife 11
ElsaLys Biotech Raises Additional USD3 Million in Financing Round 12
ElsaLys Biotech Raises US$2.7 Million In First Round Of Financing 13
Laboratoires Thea Enters into Licensing Option Agreement with Elsalys Biotech 15
Elsalys Biotech Enters into Licensing Agreement with Transgene 16
ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 17
Elsalys Biotech Files Registration Statement to Raise Funds in IPO 18
Transgene Acquires 37% Stake in ElsaLys Biotech 19
Elsalys Biotech SA, Key Competitors 20
Elsalys Biotech SA, Key Employees 21
Elsalys Biotech SA, Other Locations 22

List of Figures
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Elsalys Biotech SA:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C11275)販売に関する免責事項を必ずご確認ください。
★調査レポート[Elsalys Biotech SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆